Future of Merck KGaA/Pfizer’s Bavencio at risk despite bladder trial success

Despite the drug’s approved use in the first-line treatment of renal cell carcinoma, its position in genitourinary malignancies is hampered by the presence of other established brands. Credit: Shutterstock + Natali_Mis.